Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo‐controlled superiority study (VANISH 306)

OBJECTIVE: To evaluate the efficacy and safety of ibrexafungerp versus placebo for acute vulvovaginal candidiasis (VVC) treatment. DESIGN: Global phase 3, randomised, placebo‐controlled superiority study. SETTING: Study sites in the USA (n = 19) and Bulgaria (n = 18). POPULATION: Female patients age...

Descripción completa

Detalles Bibliográficos
Autores principales: Sobel, R, Nyirjesy, P, Ghannoum, MA, Delchev, DA, Azie, NE, Angulo, D, Harriott, IA, Borroto‐Esoda, K, Sobel, JD
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Randomised Controlled Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299454/
https://www.ncbi.nlm.nih.gov/pubmed/34676663
http://dx.doi.org/10.1111/1471-0528.16972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299454/
https://www.ncbi.nlm.nih.gov/pubmed/34676663
http://dx.doi.org/10.1111/1471-0528.16972

Ejemplares similares